10-Q: Sonoma Pharma Reports Q1 Loss Amid Cash Burn Concerns

Sonoma Pharmaceuticals, Inc. reported increased revenue but a wider net loss and significant cash burn, raising substantial doubt about its ability to continue as a going concern.

Summary

• Revenue for the three months ended June 30, 2025, increased by 18% to $4.015 million, up from $3.391 million in the prior year period.
• Net loss widened to $1.241 million for the quarter, compared to a net loss of $1.143 million in the same period last year.
• Gross profit increased by 12% to $1.464 million, but the gross profit margin decreased from 39% to 36%.
• Cash and cash equivalents decreased significantly to $3.605 million at June 30, 2025, from $5.374 million at March 31, 2025.
• Net cash used in operating activities more than doubled to $2.015 million, up from $912,000 in the prior year period.
• The company's accumulated deficit reached $199.047 million as of June 30, 2025.
• Management has expressed substantial doubt about the company's ability to continue as a going concern within one year.
• The company continues to expand its product lines and distribution agreements, including new products for dermatology, wound care, and animal health, and partnerships with WellSpring Pharmaceutical Corporation and Medline Industries, LP.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the explicit 'going concern' warning, significant increase in cash burn from operations, and widening net loss, despite some revenue growth. The liquidity position is precarious, indicating high financial risk.

Positives

• Total revenue increased by 18% to $4.015 million for the quarter ended June 30, 2025, compared to $3.391 million in the prior year.
• United States revenue saw a significant increase of 57% to $1.005 million, driven by human health care and over-the-counter animal health care products.
• Europe revenue increased by 14% to $1.468 million due to general increase in demand.
• Asia revenue grew by 39% to $662,000, primarily due to timing of orders.
• Rest of the World revenue surged by 204% to $316,000, also due to timing of customer orders.
• Loss from operations improved to $(1.095) million from $(1.173) million in the prior year.
• Selling, general and administrative expenses decreased by 2% to $1.965 million due to ongoing cost containment efforts.
• The company expanded its Microcyn Negative Pressure Wound Therapy Solution products line in April 2024.
• New distribution agreements were established with Medline Industries, LP (August 2024) for wound care products in the US and Canada, and with WellSpring Pharmaceutical Corporation (January 2025) for Microcyn technology-based products to large US retailers, with subsequent amendments to include additional products.

Negatives

• Net loss increased to $1.241 million for the three months ended June 30, 2025, compared to $1.143 million in the prior year.
• Gross profit margin decreased to 36% from 39% in the prior year period.
• Cash and cash equivalents decreased by $1.769 million during the quarter, from $5.374 million to $3.605 million.
• Net cash used in operating activities significantly increased to $2.015 million, more than double the $912,000 used in the prior year period, primarily due to increases in accounts receivable, inventories, and prepaid expenses.
• Working capital decreased to $8.259 million from $8.552 million.
• The company's accumulated deficit grew to $199.047 million.
• Latin America revenue decreased by 36% to $564,000, primarily due to timing of customer orders for overflow manufacturing.
• Research and development expenses increased by 26% to $594,000 due to increased product development, contributing to higher operating costs.
• Other (expense) income, net, shifted from a positive $176,000 in the prior year to a negative $(147,000) in the current period, primarily due to exchange rate fluctuations despite recognition of employee retention credits.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern within one year due to its history of losses and significant cash usage in operations.
• Dependence on a small number of key customers for a significant portion of revenues, which may fluctuate unpredictably.
• Exposure to foreign currency devaluation risks, particularly for the Mexico Peso and the Euro versus the US dollar.
• A substantial Mexico tax liability, intercompany debt, unpaid technical assistance charges, and accrued interest are due in 2027, which could materially impact financial condition.
• The company's ability to raise additional capital through public or private equity offerings, debt financings, or corporate collaborations is uncertain, and such financings may not be available on commercially acceptable terms.
• Potential negative impact on the company's ability to raise capital if the economic climate in the U.S. deteriorates.
• If unable to secure additional capital, the company may be forced to reduce costs, which could cause significant delays in commercializing products and realizing its business plan.
• Risks associated with the progress and timing of development programs, regulatory approvals, clinical trials, and physician studies for products.
• Challenges in competing with other companies developing or selling competitive products.
• Risks related to protecting intellectual property and operating without infringing on the intellectual property of others.
• Risks associated with conducting a significant portion of business outside the United States, including fluctuations in foreign currency exchange rates and global economic conditions.

Future Outlook

Management believes the company has access to additional capital resources through potential public or private equity offerings, debt financings, or corporate collaborations, but cannot assure availability on commercially acceptable terms. If unable to secure additional capital, the company may need to implement further cost reduction measures, which could significantly delay product commercialization efforts critical to its business plan and future operations. The company continues to evaluate the impact of the One Big Beautiful Bill Act (OBBBA) tax reform legislation, with certain provisions effective in 2025 and others through 2027, anticipating an insignificant impact to deferred tax assets and liabilities and income taxes payable in the period of enactment.

Management Comments

• Management believes that the Company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms, if needed.
• If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations.
• These measures could cause significant delays in the Company's continued efforts to commercialize its products, which is critical to the realization of its business plan and the future operations of the Company.
• This uncertainty along with the Company's history of losses indicates that there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.
• Regarding the substantial Mexico tax liability, intercompany debt, unpaid technical assistance charges, and accrued interest due in 2027, management believes there are sufficient assets on the balance sheet to cover any tax obligation without interrupting operations or business, and has engaged tax professionals to review options to limit exposure.

Industry Context

Sonoma Pharmaceuticals operates in the global healthcare market, specializing in stabilized hypochlorous acid (HOCl) products. The company's strategy of partnering with distributors globally and expanding into diverse applications like wound care, dermatology, animal health, and disinfectants aligns with trends towards specialized, clinically-proven solutions. The focus on non-toxic, safe products like HOCl positions it within the growing demand for natural and environmentally friendly healthcare solutions. The expansion of disinfectant products, particularly with EPA approvals for various pathogens, reflects a response to ongoing public health concerns and the need for effective surface sanitization.

Comparison to Industry Standards

• The company's gross profit margin of 36% is lower than typical specialty pharmaceutical companies, which often achieve gross margins in the 70-90% range due to high intellectual property value and lower cost of goods sold for patented drugs. Sonoma's manufacturing-heavy model for HOCl products likely contributes to this difference.
• The significant cash burn from operations ($2.015 million in a quarter) for a company with $4.015 million in revenue indicates a high operating expense structure relative to its sales volume, which is common for development-stage or rapidly expanding biotech/pharma companies, but unsustainable without external funding.
• The 'going concern' warning is a critical indicator of financial distress, placing Sonoma Pharmaceuticals significantly below industry standards for financial stability and liquidity, where established companies typically demonstrate consistent profitability and positive operating cash flows.

Legal Proceedings

• The company may be involved in legal matters arising in the ordinary course of business, including matters involving proprietary technology. While currently believed to be insignificant, such matters could have a material adverse effect on business and financial condition.

Stakeholder Impact

• **Shareholders:** Face significant risk of value erosion due to the 'going concern' warning, increased losses, and potential need for dilutive capital raises. The reverse stock split in August 2024 already impacted share count.
• **Employees:** Potential for cost reduction measures and delays in product commercialization could impact job security or growth opportunities.
• **Customers:** Continued product availability and support may be at risk if the company faces severe financial constraints or is unable to secure necessary capital.
• **Suppliers:** Risk of delayed payments or renegotiated terms if the company's financial condition deteriorates further.
• **Creditors:** Increased risk of default on existing debt obligations, particularly the short-term note for insurance premiums and the substantial Mexico tax liability due in 2027.

Next Steps

• Secure additional capital through public or private equity offerings, debt financings, or corporate collaborations to sustain operations and meet obligations.
• Continue efforts to reduce costs to conserve cash.
• Commercialize products to realize the business plan and ensure future operations.
• Address the substantial Mexico tax liability, intercompany debt, and unpaid technical assistance charges due in 2027.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) tax reform legislation on consolidated financial statements.
• Adopt Accounting Standards Update (ASU) 2023-09 in the Annual Report on Form 10-K for the fiscal year ended March 31, 2026.

Key Dates

Recommendation

The 'going concern' warning is the most critical factor, indicating severe financial instability and a high risk of business failure or significant restructuring. Despite revenue growth, the widening net loss and substantial increase in cash used in operations demonstrate an unsustainable financial trajectory. The company's cash reserves are rapidly depleting, and while management mentions potential capital raises, there's no assurance of success or favorable terms. A seasoned investor would view these fundamental issues as outweighing any positive operational developments, necessitating an immediate exit to preserve capital.

Keywords

Pharmaceuticals, Healthcare, Hypochlorous Acid, HOCl, Wound Care, Dermatology, Animal Health, Disinfectants, SEC Filing, 10-Q, Financial Results, Biotech, Medical Devices, Specialty Pharma